Latest Regulatory Filings News

Cleo Diagnostics reports steady progress in its ovarian cancer diagnostic test development, with clinical trial recruitment on track and strategic access to major biobanks enhancing its regulatory pathway.

Strickland Metals plans a capital return by distributing 1.2 billion Gateway Convertible Preference Shares to its shareholders, significantly reducing its stake and reshaping ownership. The move awaits shareholder approval and hinges on conditions tied to an asset sale agreement.

29Metals Limited's June Quarter 2025 report highlights steady production at Golden Grove with revised capital guidance, while Capricorn Copper remains suspended but progresses on key environmental and regulatory fronts.

Clean Seas Seafood Limited shares have been suspended from the ASX following Federal Court approval of its acquisition by Yumbah Aquaculture Ltd, marking a significant consolidation in Australia’s seafood sector.

Imagion Biosystems has received encouraging feedback from the FDA on its MagSense HER2 breast cancer imaging program, clearing the path for a Phase 2 clinical trial and fast-tracking manufacturing.

INOVIQ Limited reports strong clinical validation for its EXO-OC ovarian cancer screening test and promising preclinical results for CAR-exosome therapeutics targeting aggressive cancers.

Tissue Repair Limited has secured major distribution partnerships in Australia, New Zealand, and Thailand for its TR Pro+® product line, marking a pivotal shift from development to commercialisation. The company is also scaling up manufacturing and advancing regulatory approvals to support its global expansion ambitions.

Imricor Medical Systems has secured key European regulatory approvals for its second-generation NorthStar system and initiated its commercial launch, while US FDA submissions progress amid some delays.

ASX Compliance has formally questioned Rewardle Holdings Limited over delayed disclosures, financial inconsistencies, and governance concerns tied to its investments in Pepper Leaf, Beanhunter, and CloudHolter.

Orthocell Limited has reported a record FY2025 revenue of A$9.19 million, driven by strong sales of its nerve repair product Remplir™ in Australia and a promising US market launch following FDA clearance.

Hydralyte USA has placed 39.5 million shortfall shares at $0.01 each, boosting total funds raised under its recent Rights Issue to nearly $559,000. The move strengthens the company’s capital position amid ongoing growth efforts.

Medallion Metals reports standout gold and copper assays from Harbour View infill drilling, reinforcing resource confidence ahead of a July update and advancing its strategic Forrestania acquisition.